ArticleFEBS open bio2026
Antibiofilm activity of a chionodracine-derived peptide by NMR-based metabolomics of cell-free supernatant of Acinetobacter baumannii clinical strains.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The ability of Acinetobacter baumannii to form biofilm is correlated with its antimicrobial resistance. The identification of antimicrobial drugs acting on biofilm is crucial to develop effective therapies. Previously, we determined that a chionodracine-derived peptide, KHS-Cnd, was able to impair A. baumannii biofilm formation. Here, to investigate the physiological changes underlying this activity, extracellular metabolite profiles of four A. baumannii strains were analyzed by NMR during biofilm formation in the presence of KHS-Cnd. Metabolites involved in biofilm energy metabolism were found extracellularly after KHS-Cnd treatment. Significantly altered pathways were associated with glyoxylate/dicarboxylate and branched-chain/aromatic amino acid metabolism. Overall, differences in extracellular metabolites reflect modifications of biofilm metabolism due to peptide treatment, thus highlighting its therapeutic potential against A. baumannii biofilm-sustained infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.